Is hydroxychloroquine a factor in South Korea’s relative success in fighting COVID-19?
Saturday, April 25, 2020
By Remaya Campbell
Copy link
Copy featured image
NO
Hydroxychloroquine is an anti-malarial drug prescribed for the treatment of lupus and rheumatoid arthritis. Its effect against COVID-19 has not been widely verified in clinical trials, and reports about it have been largely anecdotal and/or misinterpreted. South Korea is one of several countries in which hydroxychloroquine has been administered to some coronavirus patients. Studies exploring the drug’s effectiveness have yielded inconclusive results in the United States, France and China.
Public health authorities, including the World Health Organization, attribute South Korea’s relative success against COVID-19 to an early coordinated public-health response using testing, contact tracing and isolation of cases.
This fact brief is responsive to conversations such as this one.
Sources
ABOUT THE CONTRIBUTOR
Between 2020 and 2022, under close editorial supervision, Gigafact contracted a group of freelance writers and editors to test the concepts for fact briefs and provide inputs to our software development process. We call this effort Gigafact Foundry. Over the course of these two years, Gigafact Foundry writers published over 1500 fact briefs in response to claims they found online. Their important work forms the basis of Gigafact formats and editorial guidelines, and is available to the public on Gigafact.org. Readers should be aware that while there is still a lot of relevant information to be found, not all fact briefs produced by Gigafact Foundry reflect Gigafact's current methods and standards for fact briefs. If you come across any that you feel are out of date and need to be looked at with fresh eyes, don't hesitate to contact us at support@gigafact.org.
FACT BRIEF BY
